Related Experiment Video
Updated: Aug 21, 2026
An Efficient and High Yield Method for Isolation of Mouse Dendritic Cell Subsets
Published on: April 18, 2016
CNI-1493 mediated suppression of dendritic cell activation in vitro and in vivo
Elisabeth Zinser1, Nadine Turza, Alexander Steinkasserer
1Department of Dermatology, University Hospital Erlangen, Hartmannstrasse 14, D-91052 Erlangen, Germany. elisabeth.zinser@derma.imed.uni-erlangen.de
Insights
The anti-inflammatory compound CNI-1493 impacts dendritic cell (DC) biology, reducing their T-cell stimulation. This compound also effectively prevented paralysis in an experimental autoimmune encephalomyelitis (EAE) mouse model.
Area of Science:
- Immunology
- Pharmacology
Background:
- CNI-1493 is a tetravalent guanylhydrazone known to inhibit macrophage activation and reduce inflammation.
- Dendritic cells (DCs) are crucial antigen-presenting cells (APCs) that initiate T-cell responses through maturation.
Purpose of the Study:
- To investigate the novel effects of CNI-1493 on dendritic cell (DC) biology and function.
- To evaluate the therapeutic potential of CNI-1493 in an in vivo model of autoimmune disease.
Main Methods:
- In vitro analysis of DC maturation markers (e.g., CD83) and T-cell stimulation in the presence of CNI-1493.
- In vivo assessment of CNI-1493 efficacy in the experimental autoimmune encephalomyelitis (EAE) mouse model using prophylactic and early therapeutic treatment regimens.
Main Results:
- CNI-1493 treatment reduced the expression of the DC maturation marker CD83.
- In vitro, CNI-1493-treated DCs showed significantly reduced T-cell stimulation capacity.
- In vivo, CNI-1493 administration nearly completely prevented EAE-induced paralysis and reduced clinical symptoms when applied therapeutically.
Conclusions:
- CNI-1493 modulates dendritic cell (DC) biology and function, impacting their ability to stimulate T cells.
- These findings highlight CNI-1493's potential as a therapeutic agent for autoimmune diseases by targeting DC-mediated immune responses.
Abstract:
The tetravalent guanylhydrazone CNI-1493 (CNI-1493) has been shown to inhibit macrophage activation, reduce systemic inflammation as well as proinflammatory cytokine production. Here we report for the first time that CNI-1493 also influences the biology of dendritic cells (DC). In order to become potent T cell stimulators of DC have to mature. Interestingly, when CNI-1493 was added to the maturation stimulus the expression of a typical DC-maturation marker i.e. CD83 was reduced. Subsequent functional in vitro analyses showed that DC-mediated T-cell stimulation was clearly reduced in CNI-1493-treated DC, underlining the functional impact that CNI-1493 on DC biology. Furthermore, the effect of CNI-1493 was analyzed in vivo using the experimental autoimmune encephalomyelitis (EAE) model in C57BL/6 mice. Interestingly, in a prophylactic treatment regimen CNI-1493 prevented the paralysis associated with EAE almost completely. In addition, when applied in an early therapeutic setting CNI-1493 also reduced the clinical EAE symptoms. In summary, we show for the first time, that in addition to the earlier reported effects on macrophages, CNI-1493 also influences the function and biology of DC. Since DC are the only antigen-presenting cells (APC) known today to be able to prime naive T cells, the findings reported herein are highly relevant for the therapeutic application of CNI-1493.
